Direct-Acting Oral Anticoagulants: A Resident-Based Workshop to Improve Knowledge and Confidence
Introduction Direct-acting oral anticoagulant (DOAC) prescriptions have increased steadily since the first, dabigatran, was Food and Drug Administration-approved in 2010. They have multiple advantages over vitamin K antagonists including fixed dosing without coagulation lab monitoring, rapid onset a...
Main Authors: | Irsk Anderson, Vineet M. Arora |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of American Medical Colleges
2020-09-01
|
Series: | MedEdPORTAL |
Subjects: | |
Online Access: | http://www.mededportal.org/doi/10.15766/mep_2374-8265.10981 |
Similar Items
-
Direct-acting oral anticoagulants in antiphospholipid syndrome
by: T. M. Reshetnyak, et al.
Published: (2021-01-01) -
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!
by: Mahmoud Abdelnabi, et al.
Published: (2022-03-01) -
Medication errors associated with direct-acting oral anticoagulants: analysis of data from national pharmacovigilance and local incidents reporting databases
by: Abdulrhman Alrowily, et al.
Published: (2021-12-01) -
Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant
by: Roy Taoutel, et al.
Published: (2022-12-01) -
DIRECT ORAL ANTICOAGULANTS
by: I. Tzoran, et al.
Published: (2016-06-01)